Radioisotope Production (Radium-223)

Ra-223 decays by alpha emission with a half-life of 11.4 days. It is typically produced from actinium-225 or thorium-229 decay chains. The resulting Ra-223 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of actinium or thorium sources and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials, particularly alpha emitters. Accessibility for developing countries is limited by the specialised facilities and regulatory requirements.

Ra-223 production and application are well-established, with use in targeted alpha therapy.

Ra-223 is a radioactive isotope that emits alpha particles, requiring careful handling and shielding to minimise radiation exposure, particularly internal exposure.

While Ra-223 is not a proliferation concern, proper control and monitoring are necessary to prevent unauthorised access or misuse.

Traditional IAEA safeguards are not directly applicable due to the absence of fissile materials. However, monitoring and verification of the production and use of Ra-223 may be considered to ensure transparency and prevent misuse.